RenovoRx (RNXT) Revenue (2025 - 2026)
RenovoRx (RNXT) posted Revenue of $563000.0 for Q1 2026, up 136.55% sequentially from $238000.0 in Q4 2025, and up 185.79% YoY from $197000.0 in Q1 2025.
RenovoRx (RNXT) Revenue (2025 - 2026) Analysis & Trends
RenovoRx has reported Revenue for 2 years, with the latest figure at $563000.0 in Q1 2026.
- Quarterly Revenue rose 185.79% year-over-year to $563000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $1.1 million, up 2511.63% from the prior year.
- Revenue climbed to $563000.0 in Q1 2026 per RNXT's latest filing, from $238000.0 in the prior quarter.
- Over five years, Revenue peaked at $563000.0 in Q1 2026 and troughed at $197000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | 909,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 909,000.00 |
| Mar 31, 2026 | 563,000.00 |
| Dec 31, 2025 | 238,000.00 |
| Sep 30, 2025 | 266,000.00 |
| Jun 30, 2025 | 422,000.00 |
| Mar 31, 2025 | 197,000.00 |